Effective at the close of business on Friday, Feb. 28, 2025, the common shares of RepliCel Life Sciences Inc. will be delisted from the TSX Venture Exchange at the request of the company.

The voluntary delisting has been accepted by the company's board of directors with a resolution dated Feb. 5, 2025. Furthermore, the delisting of the company's common shares was approved by the majority of the minority shareholders at the annual general and special shareholders meeting held on Jan. 16, 2025.

For further information, please refer to the company's management information circular dated Nov. 27, 2024, and the news releases dated March 18, 2024, Aug. 29, 2024, Dec. 20, 2024, Jan. 16, 2025, and Feb. 14, 2025, which are available under the company's profile on SEDAR+.